Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
12.21B
Market cap12.21B
Price-Earnings ratio
31.34
Price-Earnings ratio31.34
Dividend yield
Dividend yield
Average volume
3.09M
Average volume3.09M
High today
$107.96
High today$107.96
Low today
$105.50
Low today$105.50
Open price
$106.39
Open price$106.39
Volume
2.42M
Volume2.42M
52 Week high
$107.96
52 Week high$107.96
52 Week low
$61.23
52 Week low$61.23

Stock Snapshot

Halozyme Therapeutics(HALO) stock is priced at $107.50, giving the company a market capitalization of 12.21B. It carries a P/E multiple of 31.34.

On 2026-08-19, Halozyme Therapeutics(HALO) stock moved within a range of $105.50 to $107.96. With shares now at $107.50, the stock is trading +1.9% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 2.42M, compared to an average daily volume of 3.09M.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $107.96 and a low of $61.23.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $107.96 and a low of $61.23.

HALO News

Simply Wall St 11h
Halozyme Therapeutics Adds A New Director, Is It 21% Overvalued? - simplywall.st

...

Halozyme Therapeutics Adds A New Director, Is It 21% Overvalued? - simplywall.st
TipRanks 2d
Halozyme Earnings Call Highlights Surging Royalties, Raised Outlook

Halozyme Therapeutics ((HALO)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful...

The Motley Fool 6d
Halozyme Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Tram Bui President and Chief Exe...

Halozyme Q2 2026 Earnings Call Transcript

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.